IMM 1.49% 34.0¢ immutep limited

Positive broker

  1. 39 Posts.
    He is on The Bull and has a Hold recommendation on PRR

    I hope others catch wind of this analysis. I say Buy! Not Bye

    Les Szancer - Paradigm Securities 6/10/2014

    After four years, PRR was granted a US patent for its ovarian cancer treatment drug CVac. The patent extends to 2022. Prima is at various stages of development in different parts of the world. This is a long-winded process, but I think we can now see light at the end of that long tunnel.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.